Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Stroke Patients Who Have Swallowing Problems Less Likely To Develop Chest Infections Thanks To New Technology
Recovering stroke patients and others who find it hard to swallow when they eat and drink are now at a lower risk of developing pneumonia or chest infections, thanks to new technology which will help assess and treat their swallowing difficulties. Many patients suffering from stroke, head injury or major trauma often have swallowing difficulties when food and drink can go down the wrong way - patients can later develop nasty chest infections and pneumonias.
generic viagra online
Louisiana House Approves Bill Allowing Providers To Refuse Certain Reproductive Health Services
The Louisiana House on Tuesday voted 82-13 to approve legislation (HB 517) that would allow some health professionals to refuse to provide certain medical services that they object to on religious or moral grounds, the New Orleans Times-Picayune reports.The House-passed bill is an amended version of a measure, introduced by Rep. Bernard LeBas (D), that a House committee rejected earlier this month. The revised bill narrowed the list of procedures that can be denied, and it applies to health providers only in public facilities, not religious health facilities statewide as in the original bill. Under the bill, public health care employees would be allowed to decline to provide abortions or abortifacient drugs. They also would be allowed to refuse participation in embryonic stem cell research or cloning, euthanasia and physician-assisted suicide. Public employees would be immune from civil lawsuits and have job security under the measure.According to the Times-Picayune, Gov. Bobby Jindal"s (R) administration backed the original bill in committee, although state Health Secretary Alan Levine indicated that the bill"s original provisions were too broad. Under the original measure, health care providers would have been allowed to refuse services such as artificial insemination, sterilization, artificial reproductive technologies and "dispensation of drugs affecting the reproductive process." The original measure also would have covered both public and private health care providers (Barrow, New Orleans Times-Picayune, 5/20).Prior to passage, the House approved an amendment to narrow the scope of the bill offered by Rep. John Bel Edwards (D), who said that the original bill"s provisions were not specific enough and could pose problems for private businesses. He also said that the original bill would have posed barriers to patients seeking access to basic treatments and medications (AP/New Orleans Times-Picayune, 5/19). The measure now advances to the state Senate for debate (New Orleans Times-Picayune, 5/20). Drugshop to buy zoloft online and other pills.
News of the day
Environmental Factors Instruct Lineage Choice Of Blood Progenitor Cells
The research team led by Dr. Timm Schroeder, stem cell researcher at Helmholtz Zentrum MÃønchen, has developed a new bioimaging method for observing the differentiation of hematopoietic progenitor cells (HPC) at the single-cell level. With this method the researchers were able to prove for the first time that not only cell-intrinsic mechanisms, but also external environmental factors such as growth factors can control HPC lineage choice directly. The findings, published in the current issue of the prestigious journal Science, provide an essential building block for understanding the molecular mechanisms of hematopoiesis and are an important prerequisite for optimizing therapeutic stem cell applications.
Medical Devices

Ablynx Announces A Novel Preclinical Development Candidate Targeting IL6R

Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced that it has advanced ALX-0061, a new Nanobody®-based therapeutic programme, into preclinical development for the treatment of autoimmune and inflammatory diseases. ALX-0061 is a selective, low molecular weight biologic, binding to the IL6 receptor (IL6R). It has a very high potency and demonstrated a favourable PD, PK and safety profile in preclinical testing compared with the benchmark molecule. ALX-0061 has no Fc-mediated effector function which may translate into an improved safety profile. It also avoids cross-linking IL6R due to its monovalent binding to the target. The low molecular weight and desirable biophysical properties of this Nanobody® open up opportunities for alternative routes of administration and superior tissue penetration in the clinical setting. The Nanobody® can be manufactured at a relatively low cost in a microbial system. "We are delighted to strengthen our product portfolio by advancing another novel Nanobody®, discovered using our proprietary Nanobody® platform, into preclinical development. It is well positioned to translate into a superior treatment for rheumatoid arthritis and other autoimmune diseases. There are already three Nanobodies® in clinical development, with our lead programme, ALX-0081, a novel anti-thrombotic, on track to start Phase II in the next few months", commented Dr. Edwin Moses, Chief Executive Officer and Chairman of Ablynx. About ALX-0061 (IL6R) ALX-0061 is a Nanobody® binding to the interleukin-6 receptor (IL6R). It has the potential to differentiate through its high potency, high stability and low molecule weight of only 26kD which should translate into superior tissue penetration, attractive PK/PD and superior safety and efficacy profile compared with a benchmark monoclonal antibody. The involvement of the IL6 pathway in a variety of diseases indicates that multiple indications can be pursued with large market potential including rheumatoid arthritis (RA), Crohn"s disease, Castleman"s disease, multiple myeloma and systemic lupus erythematosus (SLE). College Hill Life Sciences


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009